Regulatory Focus™ > News Articles > 2019 > 1 > Recon: Louisiana Adopts ‘Netflix’ Model to Pay for Hepatitis C Drugs

Recon: Louisiana Adopts ‘Netflix’ Model to Pay for Hepatitis C Drugs

Posted 11 January 2019 | By Ana Mulero 

Recon: Louisiana Adopts ‘Netflix’ Model to Pay for Hepatitis C Drugs

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. 

In Focus: US
  • Samsung Faces Resistance From Big Pharma in the U.S. (WSJ)
  • J&J raises U.S. prices on around two dozen drugs (Reuters) (BioPharma Dive)
  • Louisiana adopts ‘Netflix’ model to pay for hepatitis C drugs (The Washington Post) (STAT-$)
  • Teva shells out $135M to wrap Illinois AG's Medicaid pricing fraud suit (Fierce)
  • US FDA's Biosimilars Chief Leah Christl Plans Departure (Pink Sheet-$)
  • Uncertainty Grows for Biotech as Government, FDA Shutdown Drags On (Xconomy)
  • Government shutdown slows FDA inspections, food safety watchdogs warn of outbreak risks (CNBC)
  • Awak Technologies wins FDA breakthrough designation for portable PD device (MassDevice)
  • Drug pricing advocates to spend $1M on ads supporting Trump proposal (STAT)
  • Fed up with high prices, drug shortages, Advocate and other hospitals create not-for-profit drug company (Chicago Tribune)
  • M&A, IPOs and VC raises: Biotech and medtech executives look to their crystal balls for 2019 (Fierce)
In Focus: International
  • China talks pharma with India, but buys cheap drugs from other countries (Hindustan Times)
  • Flagship names ex-Roche SVP as CEO of cancer startup Cygnal (Fierce)
  • hVIVO preps phase 3 for ‘universal’ flu vaccine (Fierce)
  • EUSA Pharma buys rights to Janssen rare disease drug (pharmaphorum)
  • Health Canada places restrictions on Allergan's fibroid treatment Esmya (Reuters)
  • FT Health: Key moment for the NHS (Financial Times)
Pharmaceuticals & Biotechnology
  • Big Pharma Faces the Curse of the Billion-Dollar Blockbuster (Bloomberg)
  • Big pharma raises bet on biotech as frontier for growth (San Francisco Business Times-$)
  • Blockchain to Secure a More Personalized Pharma (GEN)
  • So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride (Endpoints)
  • A Drug That Eases Miscarriages Is Difficult For Women To Get (NPR)
  • Sanofi-Genzyme inappropriately sought confidential patient information, suit alleges (STAT-$)
  • Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation (STAT-$)
  • Want to buy Clovis? Step up. ‘Everybody knows where to find me,’ CEO says (Fierce)
  • Orchard Therapeutics' 2019: Pipeline progress, breaking ground on its $90M manufacturing site (Fierce)
  • Computational scientists design a new IL-2 cancer drug and spin it out into a biotech startup (Endpoints)
  • Drug Research and Review Issues on Radar at FDA (PharmExec)
  • Biotech stocks are off to the best start of the year since 2012 on heels of J.P. Morgan conference (CNBC)
  • A Boston biotech takes on a challenge most companies have avoided: making a better schizophrenia drug (Boston Globe)
  • Biosimilars in the US: Rising applications and approval rates (BioPharma-Reporter)
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • FDA Won't Add Black Box Warning To Blood Thinner Plavix (Law360-$)
  • Ocular Therapeutix seeks second indication for drug-delivery eye insert (DDBN)
  • Adding a 'switch' to Cas9 to make CRISPR gene editing safer (Fierce)
  • Early research suggests existing drugs could strangle building blocks of metastasis (Endpoints)
  • New leukemia drug is more effective and easier to use (Press)
  • Black Diamond Therapeutics raises $85M in Series B funding (MedCity News)
  • New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi (caplacizumab) for rare blood clotting disorder (Press)
Medical Devices
  • Third Party Review Organization Performance Report (FDA)
  • PQ Bypass raises $60M to fund PAD Detour graft tech (Fierce)
  • Empatica gets FDA clearance for epilepsy monitor in children (Medtech Dive)
  • Cantel Medical acquires dental tech dev Vista Research Group for $11m (MassDevice)
  • Tela Bio, Aroa Biosurgery win FDA nod for large-size OviTex bioscaffolds (MassDevice)
  • Digital health is attracting huge investments, but will patients buy it? (STAT-$)
  • Biodegradable Implantable Blood Flow Sensor (Medgadget)
  • Medtronic, Boston Scientific stand by stents despite critical study (Star Tribune)
US: Assorted & Government
  • Azar looking for new policy adviser as Parente nomination dies (Politico)
  • Net Effect of Expanding Medicaid (The Health Care Blog)
  • Drug Overdose Deaths Among Women Aged 30–64 Years — United States, 1999–2017 (CDC)
  • Up to 84,000 Americans hospitalized with flu in past three months: CDC (Reuters) (CDC)
 
Upcoming Meetings & Events Europe
  • Patient Safety in the NHS: Opening the Door to Change (Bill of Health)
General Health & Other Interesting Articles
  • What I Learned From Cancer (The Atlantic)
  • Hospital Mergers Get Even Bigger As Seller Size Hits $400M (Forbes)
  • Man gets 10 years for cyberattack on children’s hospital (AP News)
Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.

Need to contact the editor of Regulatory Reconnaissance? Email us at news@raps.org.

A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Categories: Regulatory News

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe